ALGEMENE GENEESKUNDE, Dr. Ch. De Reze financials
A multi-period view of the public annual-account figures reported for ALGEMENE GENEESKUNDE, Dr. Ch. De Reze, with comparable measures and links to available source documents.
Company overviewRegistry number
0448941635
Fiscal coverage
2024–2025
Public sources
cbso_bulk
Data updated
Jul 28, 2026
Financial evidence
Latest movements for ALGEMENE GENEESKUNDE, Dr. Ch. De Reze
2025 versus 2024
- Operating line
- €156,329
- EBITDA
- €123,420
- Total assets
- €616,002
- Equity
- €450,871
-0.3%
-2.7%
+0.7%
+12.3%
EBITDA margin +78.9% · Equity ratio +73.2%
Multi-year filings
Source: NBB/CBSOFiled annual accounts by fiscal year
Public regulator-filed figures across 2 years.
Fiscal year | Gross margin | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Dec 2025 | €156,329 | €123,420 | €616,002 | €450,871 | - |
| 202431 Dec 2024 | €156,728 | €126,822 | €611,993 | €401,529 | - |
Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.